The Molsheim plant in France will see its biggest effort to manufacture MilliporeSigma’s Mobius single-use assemblies and create 800 jobs.
The €130 million ($131 million) investment, the largest ever made in the site’s 50-year history, will in particular increase the capacity of Mobius’ single-use products within Merck KGaA’s life sciences business portfolio, known as MilliporeSigma in North America. .
“Molsheim is our largest life sciences campus in France. We have the in-house expertise and area to build the blank rooms to manufacture single-use (SU) assemblies. Molsheim has exclusive features that make it the right place to host this activity. in Europe,” corporate spokesman Gangolf Schrimpf told BioProcess Insider.
“It already houses the control of single-use hardware and software, as well as the manufacture of NovaSeptum (a single-use collection system). This, combined with advanced production experience in the required cleanroom environment and proven experience in achieving giant projects, reinforces this choice.
3,500 square meters of clean rooms, an administrative construction and a new logistics warehouse are expected to be operational until the end of 2024, and full production will accelerate until 2028. By then, the company says more than 800 jobs will have been created. .
According to Schrimpf, this investment plan marks the 3rd phase of industrialization through the German company Merck’s allocation of Mobius Europe at the Molsheim site, west of Strasbourg.
“In 2021, we announced the first investment in our Molsheim site, with €25 million for Fast Track Phases 1 and 2 single-use assemblies, adding 350 jobs. One of those lines opened in 2021 and two others are under construction lately.
The 3 also represents the continuation of global capacity expansions in response to the growing demand for single-use assemblies, triggered in part by industry mobilization in response to the COVID-19 pandemic.
“In April, we announced an investment of €100/110 million in single-use sets in Wuxi, China, which will be operational until 2024. Its Line 3 opened in 2021. “
The company also has one in Danvers, Massachusetts, that produces single-use components, which has experienced major expansions in recent years.
Categories: BioProcess Insider, Upstream and Downstream Processing